MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
2024年8月1日 - 10:15PM
ビジネスワイヤ(英語)
First-of-its-kind procedure a breakthrough in
expanding robotic capability to complex neurosurgical care
MMI (Medical Microinstruments, Inc.), a robotics company
dedicated to increasing treatment options and improving clinical
outcomes for patients with complex conditions, today announced the
completion of a preclinical study that demonstrated the feasibility
of the Symani® Surgical System in neurosurgical procedures.
Adnan Siddiqui, M.D., Ph.D., Chief Executive Officer and Chief
Medical Officer of the Jacobs Institute and Vice Chair and
Professor of Neurosurgery in the Jacobs School of Medicine and
Biomedical Sciences, successfully repaired a blood vessel in the
brain in an animal model using the Symani Surgical System, the
first such robotic-assisted microsurgery demonstration in the
brain.
“Dr. Siddiqui’s breakthrough demonstration showed the benefits
of robotic precision and control when operating on brain tissue,”
said Mark Toland, CEO of MMI. “The robotic platform allowed him to
perform extremely delicate maneuvers deep in the skull cavity that
would not have been possible with the human hand alone. The success
of this procedure opens the possibility of expanding Symani’s reach
into neurosurgery, a field of medicine that involves the most
fragile anatomy and has yet to benefit from robotic-assisted
microsurgical capabilities.”
The study aimed to both collect feedback on Symani from a highly
experienced neurosurgeon and assess the feasibility of the platform
as a tool to treat neurological conditions. It was performed at the
Jacobs Institute, a nonprofit medical device innovation center
located in Buffalo, N.Y., which aims to accelerate the development
of next-generation technologies in vascular medicine.
“Symani offered added control that allowed me to access and
repair a vein just under 1 millimeter in diameter, with clips
spaced 4 millimeters apart,” said Dr. Siddiqui. “It required
techniques that would be extraordinarily difficult for most
micro-neurosurgeons to replicate without robotic assistance, using
sutures so small they are barely visible to the naked eye. Based on
this excellent initial experience, I have no doubt Symani could be
highly effective during a wide range of complex neurosurgical
procedures with the development of additional microsurgical tools.
In fact, I believe it is ready for superficial temporal to middle
cerebral artery bypass surgery today.”
The Symani Surgical System is designed to provide enhanced
precision and control for the anastomosis and suturing of
microscopic vessels with the thinnest available sutures. With the
world’s smallest surgical robotic wrist, called NanoWrist®, Symani
enables surgeons to replicate the natural movements of the human
hand at the micro scale. It also features motion-scaling technology
that reduces the hand’s scale of movement by as much as 20x, giving
surgeons more freedom to operate on microscopic anatomy.
Surgeons have leveraged the Symani Surgical System in over 1,000
cases globally and more than two dozen publications highlight
positive clinical outcomes. It is designed to help restore quality
of life for patients, accelerate the number of surgeons able to
push the boundaries of complex procedures for delicate anatomy, and
enable hospitals to expand their open surgical programs.
The U.S. Food and Drug Administration (FDA) granted De Novo
Classification to the Symani Surgical System in April 2024, making
it the only commercially available platform in the U.S. for
reconstructive microsurgery. It is available for commercial use in
Europe and parts of Asia Pacific.
To learn more about MMI and the Symani Surgical System, visit
MMI’s website here: https://mmimicro.com.
About MMI
MMI (Medical Microinstruments, Inc.) is on a mission to advance
robotic technology that pushes the limits of soft tissue open
surgery and opens new opportunities for surgeons to restore quality
of life for more patients with complex conditions. The company was
founded in 2015 near Pisa, Italy, and its proprietary Symani®
Surgical System combines the world’s smallest wristed
microinstruments with tremor-reducing and motion-scaling
technologies to address significant unmet patient needs across the
globe. This first-of-its-kind surgical robotic platform for open,
soft tissue micro-level surgery can help address microvascular
repair and lymphatic repair. In Europe and APAC, it also addresses
peripheral nerve repair. The Symani System is authorized for use in
the U.S. by the FDA and is a CE Marked medical device in Europe.
MMI is backed by global investors including Fidelity Management
& Research Company, Andera Partners, BioStar, Deerfield
Management, Fountain Healthcare Partners, Panakès Partners, RA
Capital, Sambatech, and Wellington Partners.
About the Jacobs Institute
The Jacobs Institute is a non-profit organization whose mission
is to accelerate the development of next-generation technologies
for vascular and neurologic diseases through collisions of
physicians, engineers, entrepreneurs, and industry. The JI’s vision
is to improve the treatment of vascular and neurologic disease in
Western New York and the world, while fostering local economic
development. The JI fosters medical collaboration and innovation
through partnerships with the University of Buffalo (UB), Kaleida
Health, and industry to be a fitting tribute to the work and memory
of Lawrence D. Jacobs, MD. Additionally, the JI’s i2R, or Idea to
Reality Center, is taking ideas for vascular and neurologic medical
devices and moving them through the proof-of-concept process.
Finally, the JI also increases physician and industry knowledge of
vascular and neurologic diseases through clinical education
programs.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801240766/en/
Media: Dan Ventresca Matter Health for MMI MMI@matternow.com
Investor Relations: Lisa Croke Lisa.Croke@mmimicro.com